Cost-effectiveness studies in radiation therapy

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 5, 2010, Pages 567-582

  Sher, David J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

cancer; cost effectiveness analysis; decision analysis; health services research; radiation oncology; radiation therapy; utilities

Indexed keywords

BONE METASTASIS; BRAIN CANCER; BRAIN METASTASIS; BRAIN SURGERY; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIGESTIVE SYSTEM CANCER; GYNECOLOGIC CANCER; GYNECOLOGIC SURGERY; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LUNG CANCER; LUNG LOBECTOMY; LYMPHOMA; MASTECTOMY; PROSTATE CANCER; PROSTATECTOMY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; STOMACH SURGERY; TREATMENT PLANNING;

COST-BENEFIT ANALYSIS; HUMANS; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 77958184683     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.51     Document Type: Review

References (106)

1. Cancer Trends Progress Report - 2007 Update. National Cancer Institute, MD, USA (2007).
2. Cancer Facts and Figures - 2008. American Cancer Society, GA, USA (2008).
3. Meropol NJ, Schrag D, Smith TJ et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J. Clin. Oncol. 27(23), 3868-3874 (2009). • Nice summary of the issues surrounding the cost of cancer care.
4. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of trends in the cost of initial cancer treatment. J. Natl Cancer Inst. 100(12), 888-897 (2008).
5. Weinstein MC, Skinner JA. Comparative effectiveness and health care spending - implications for reform. N. Engl. J. Med. 362(5), 460-465 (2010).
6. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N. Engl. J. Med. 353(14), 1516-1522 (2005).
7. Baker GR. Localization: conventional and CT simulation. Br. J. Radiol. 79 (Spec. No 1), S36-S49 (2006).
8. Mah D, Chen CC. Image guidance in radiation oncology treatment planning: the role of imaging technologies on the planning process. Semin. Nucl. Med. 38(2), 114-118 (2008).
9. Goitein M. Future prospects in planning radiation therapy. Cancer 55 (9 Suppl.), 2234-2239 (1985).
10. Gunderson LT. Clinical Radiation Oncology. Churchill Livingstone, PA, USA (2000).
11. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J. Clin. Oncol. 24(17), 2618-2623 (2006).
12. Jereczek-Fossa BA, Krengli M, Orecchia R. Particle beam radiotherapy for head and neck tumors: radiobiological basis and clinical experience. Head Neck 28(8), 750-760 (2006).
13. Fukumura A, Tsujii H, Kamada T et al. Carbon-ion radiotherapy: clinical aspects and related dosimetry. Radiat. Prot. Dosimetry 137 (1-2), 149-155 (2009).
14. Lo SS, Fakiris AJ, Chang EL et al. Stereotactic body radiation therapy: a novel treatment modality. Nat. Rev. Clin. Oncol. 7(1), 44-54 (2008).
15. Verellen D, De Ridder M, Tournel K et al. An overview of volumetric imaging technologies and their quality assurance for IGRT. Acta Oncologica (Stockholm, Sweden), 47(7), 1271-1278 (2008).
16. Ben-Josef E, Lawrence TS. Using a bigger hammer: the role of stereotactic body radiotherapy in the management of oligometastases. J. Clin. Oncol. 27(10), 1537-1539 (2009).
17. Rusthoven KE, Kavanagh BD, Cardenes H et al. Multi-institutional Phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. 27(10), 1572-1578 (2009).
18. Heron DE, Ferris RL, Karamouzis M et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a Phase I dose-escalation trial. Int. J. Radiat. Oncol. Biol. Phys. 75(5), 1493-1500 (2009).
19. Lo SS, Cardenes HR, Teh BS et al. Stereotactic body radiation therapy for nonpulmonary primary tumors. Expert Rev. Anticancer Ther. 8(12), 1939-1951 (2008).
20. ProCure. Developing Proton Therapy Centers. ProCure, OK, USA (2009).
21. Van de Werf E, Lievens Y, Verstraete J, Pauwels K, Van den Bogaert W. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT. Radiother. Oncol. 93(1), 137-140 (2009).
22. Suh W W, Pierce LJ, Vicini FA, Hayman JA. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 62(3), 790-796 (2005).
23. Poon I, Pintilie M, Potvin M, McGowan T. The changing costs of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy. Can. J. Urol. 11(1), 2125-2132 (2004).
24. Goitein M, Jermann M. The relative costs of proton and x-ray radiation therapy. Clin. Oncol. (R. Coll. Radiol.), 15(1), S37-50 (2003).
25. Peeters A, Grutters JP, Pijls-Johannesma M et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother. Oncol. 95(1), 45-53 (2010).
26. Gold M, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
27. Stiggelbout AM, de Haes JC. Patient preference for cancer therapy: an overview of measurement approaches. J. Clin. Oncol. 19(1), 220-230 (2001).
28. Drummond MF, Sculpher M, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK (2005).
29. Pijls-Johannesma M, Pommier P, Lievens Y. Cost-effectiveness of particle therapy: current evidence and future needs. Radiother. Oncol. 89(2), 127-134 (2008).
30. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother. Oncol. 83(2), 110-122 (2007).
31. Fisher B, Dignam J, Wolmark N et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J. Clin. Oncol. 16(2), 441-452 (1998).
32. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503), 2087-2106 (2005).
33. Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N. Engl. J. Med. 356(23), 2399-2405 (2007).
34. Liljegren G, Karlsson G, Bergh J, Holmberg L. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann. Oncol. 8(8), 757-763 (1997).
35. Hayman JA, Hillner BE, Harris JR, Weeks JC. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J. Clin. Oncol 16(3), 1022-1029 (1998). • Well-performed utilities elicitation for health state after breast cancer radiotherapy.
36. Suh WW, Hillner BE, Pierce LJ, Hayman JA. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. Int. J. Radiat. Oncol. Biol. Phys. 61(4), 1054-1061 (2005).
37. Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-analytic model and costeffectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J. Clin. Oncol. 20(11), 2713-2725 (2002).
38. Hayman JA, Hillner BE, Harris JR, Pierce LJ, Weeks JC. Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer. J. Clin. Oncol 18(2), 287-295 (2000).
39. Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a costeffectiveness analysis. Int. J. Radiat. Oncol Biol. Phys. 74(2), 440-446 (2009).
40. Lundkvist J, Ekman M, Ericsson SR, Isacsson U, Jonsson B, Glimelius B. Economic evaluation of proton radiation therapy in the treatment of breast cancer. Radiother. Oncol. 75(2), 179-185 (2005).
41. Kozak KR, Smith BL, Adams J et al. Accelerated partial-breast irradiation using proton beams: initial clinical experience. Int. J. Radiat. Oncol. Biol. Phys. 66(3), 691-698 (2006).
42. Pignol JP, Olivotto I, Rakovitch E et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J. Clin. Oncol. 26(13), 2085-2092 (2008).
43. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11), 969-974 (1998).
44. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28(1), 126-131 (2010).
45. Bolla M, de Reijke TM, Van Tienhoven G et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360(24), 2516-2527 (2009).
46. Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181(3), 956-962 (2009).
47. Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol. Assess. 7(33), iii, ix-x, 1-157 (2003).
48. Konski A, Watkins-Bruner D, Feigenberg S et al. Using decision analysis to determine the cost-effectiveness of intensitymodulated radiation therapy in the treatment of intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 408-415 (2006).
49. Konski A, Speier W, Hanlon A, Beck JR, Pollack A. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J. Clin. Oncol. 25(24), 3603-3608 (2007). •• Very important study evaluating the cost-effectiveness of proton beam therapy for prostate cancer.
50. Hoffe SE, Shridhar R, Biagioli MC. Radiation therapy for rectal cancer: current status and future directions. Cancer Control 17(1), 25-34 (2010).
51. Cooke EW, Hazard L. Curative radiation therapy for pancreatic malignancies. Surg. Clin. North Am. 90(2), 341-354 (2009).
52. Willett CG, Czito BG. Chemoradiotherapy in gastrointestinal malignancies. Clin. Oncol. (R. Coll. Radiol.), 21(7), 543-556 (2009).
53. Meyer J, Willett C, Czito B. Current and emerging treatment strategies for anal cancer. Curr. Oncol. Rep. 12(3), 168-174 (2009).
54. Van Den Brink M, Van Den Hout WB, Stiggelbout AM et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group. J. Clin. Oncol. 22(2), 244-253 (2004).
55. Peeters KC, van de Velde CJ, Leer JW et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients - a Dutch colorectal cancer group study. J. Clin. Oncol. 23(25), 6199-6206 (2005).
56. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg. 93(10), 1215-1223 (2006).
57. Krzyzanowska MK, Earle CC, Kuntz KM, Weeks JC. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 67(1), 211-218 (2007).
58. Wenger U, Johnsson E, Bergquist H et al. Health economic evaluation of stent or endoluminal brachytherapy as a palliative strategy in patients with incurable cancer of the oesophagus or gastro-oesophageal junction: results of a randomized clinical trial. Eur. J. Gastroenterol. Hepatol. 17(12), 1369-1377 (2005).
59. da Silveira EB, Artifon EL. Cost-effectiveness of palliation of unresectable esophageal cancer. Dig. Dis. Sci. 53(12), 3103-3111 (2008).
60. Shenfine J, McNamee P, Steen N, Bond J, Griffin SM. A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technol. Assess. 9(5), iii, 1-121 (2005).
61. Wang SJ, Fuller CD, Choi M, Thomas CR. A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. Gastrointest. Cancer Res. 2(2), 57-63 (2008).
62. Pettersson D, Cedermark B, Holm T et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br. J. Surg. 97(4), 580-587 (2010).
63. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350(12), 1200-1210 (2004).
64. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299(9), 1019-1026 (2008).
65. Yovino S, Poppe M, Jabbour S et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int. J. Radiat. Oncol. Biol. Phys. 72 (1 Suppl. 1), S254 (2010).
66. Konski A, Kachnic LA. Jury still out on whether advanced technology can improve the outcomes of patients with anal canal cancer. Oncology (Williston Park), 23(12), 1092, 1094, 1096 (2009).
67. Smolle-Juettner FM, Maier A, Lindenmann J, Matzi V, Neubock N. Resection in stage I/II non-small cell lung cancer. Front Radiat. Ther. Oncol. 42, 71-77 (2009).
68. Serke M. Adjuvant therapy in early-stage non-small cell lung cancer. Front. Radiat. Ther. Oncol. 42, 135-144 (2008).
69. Senan S, Lagerwaard F. Stereotactic radiotherapy for stage I lung cancer: current results and new developments. Cancer Radiother. 14(2), 115-118 (2010).
70. Auperin A, Le Pechoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28(13), 2181-2190 (2009).
71. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a Phase III randomised controlled trial. Lancet 374(9687), 379-386 (2009).
72. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med. 341(7), 476-484 (1999).
73. Pijls-Johannesma M, Grutters JP, Lambin P, Ruysscher DD. Particle therapy in lung cancer: where do we stand? Cancer Treat. Rev. 34(3), 259-267 (2008).
74. Ferguson MK. Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis. J. Thorac. Cardiovasc. Surg. 126(6), 1935-1942 (2003).
75. Tai TH, Yu E, Dickof P et al. Prophylactic cranial irradiation revisited: costeffectiveness and quality of life in small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 52(1), 68-74 (2002).
76. Coy P, Schaafsma J, Schofield JA. The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 48(4), 1025-1033 (2000).
77. van den Hout WB, Kramer GW, Noordijk EM, Leer JW. Cost-utility analysis of short-versus long-course palliative radiotherapy in patients with non-smallcell lung cancer. J. Natl Cancer Inst. 98(24), 1786-1794 (2006). •• Excellent example of trial-based cost-effectiveness analysis in radiotherapy.
78. Grutters JP, Pijls-Johannesma M, Ruysscher DD et al. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev. 36(6), 468-476 (2010).
79. Zhang X, Li Y, Pan X et al. Intensitymodulated proton therapy reduces the dose to normal tissue compared with intensitymodulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int. J. Radiat. Oncol. Biol. Phys. 77(2), 357-366 (2010).
80. Alektiar KM. When and how should adjuvant radiation be used in early endometrial cancer? Semin. Radiat. Oncol 16(3), 158-163 (2006).
81. Barbera L, Thomas G. Management of early and locally advanced cervical cancer. Semin. Oncol. 36(2), 155-169 (2009).
82. Chen MF, Tseng CJ, Tseng CC, Kuo YC, Yu CY, Chen WC. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int. J. Radiat. Oncol. Biol Phys. 67(5), 1438-1444 (2007).
83. Ng AK, Li S, Neuberg D, Silver B, Weeks J, Mauch P. Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians. Ann. Oncol 15(2), 261-269 (2004).
84. Ng AK, Mauch PM. Role of radiation therapy in localized aggressive lymphoma. J. Clin. Oncol. 25(7), 757-759 (2007).
85. Norum J, Angelsen V, Wist E, Olsen JA. Treatment costs in Hodgkin's disease: a cost-utility analysis. Eur. J. Cancer 32 A (9), 1510-1517 (1996).
86. Ng AK, Kuntz KM, Mauch PM, Weeks JC. Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease. Int. J. Radiat. Oncol. Biol. Phys. 50(4), 979-989 (2001).
87. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J. Nucl. Med. 50 (Suppl. 1), 21S-30S (2009).
88. Gil Z, Fliss DM. Contemporary management of head and neck cancers. Isr. Med. Assoc. J. 11(5), 296-300 (2009).
89. Tao Y, Daly-Schveitzer N, Lusinchi A, Bourhis J. Advances in radiotherapy of head and neck cancers. Curr. Opin. Oncol. 22(3), 194-199 (2010).
90. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother. Oncol. 85(1), 156-170 (2007).
91. Kam MK, Leung SF, Zee B et al. Prospective randomized study of intensitymodulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J. Clin. Oncol. 25(31), 4873-4879 (2007).
92. Widesott L, Pierelli A, Fiorino C et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int. J. Radiat. Oncol. Biol. Phys. 72(2), 589-596 (2008).
93. Hoffman KE, Yock TI. Radiation therapy for pediatric central nervous system tumors. J. Child. Neurol. 24(11), 1387-1396 (2009).
94. Pollack IF. Brain tumors in children. N. Engl. J. Med. 331(22), 1500-1507 (1994).
95. Geyer JR, Sposto R, Jennings M et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J. Clin. Oncol. 23(30), 7621-7631 (2005).
96. Rutkowski S, Bode U, Deinlein F et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med. 352(10), 978-986 (2005).
97. Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer 103(4), 793-801 (2005). • This may end up as the only cost-effectiveness analysis to show proton beam therapy is cost effective for treating cancer.
98. Gaspar LE, Mehta MP, Patchell RA et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 96(1), 17-32 (2010).
99. Mehta M, Noyes W, Craig B et al. A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for singlebrain metastases. Int. J. Radiat. Oncol. Biol. Phys. 39(2), 445-454 (1997).
100. Hartsell WF, Scott CB, Bruner DW et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst. 97(11), 798-804 (2005).
101. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother. Oncol. 52(2), 111-121 (1999).
102. Ryu S, Jin R, Jin JY et al. Pain control by image-guided radiosurgery for solitary spinal metastasis. J. Pain Symptom Manage. 35(3), 292-298 (2008).
103. van den Hout WB, van der Linden YM, Steenland E et al. Single-versus multiplefraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J. Natl Cancer Inst. 95(3), 222-229 (2003).
104. Konski A, James J, Hartsell W et al. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases. Am. J. Clin. Oncol. 32(4), 423-428 (2009).
105. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 60(5), 1373-1378 (2004).
106. Grutters JP, Kessels AG, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother. Oncol. 95(1), 32-40 (2010).